Standard Operating Procedure: Process for applying for Proton Beam Therapy and subsequent treatment centre allocation for eligible patients

Similar documents
Specialised Services Service Specification: CP146 Proton Beam Therapy

Specialised Services Commissioning Policy: CP160 Specialised Paediatric Neurological Rehabilitation

Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013

Methods: Commissioning through Evaluation

Implementation of the right to access services within maximum waiting times

S2 and Directive routes: guidance for commissioners

Prescribed Connections to NHS England

Specialised Services: CPL-008 Referral Management Policy

REFERRAL TO TREATMENT ACCESS POLICY

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers

Northern Ireland Peer Review of Cancer MDTs. EVIDENCE GUIDE FOR LUNG MDTs

Islington CCG Commissioning Statement in relation to the commissioning of health services for children and young people 0-18 years

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Named Key Worker for Cancer Patients Policy

Methods: National Clinical Policies

Manual for Cancer Services Teenage and Young Adults Measures. Version 1.0

OFFICIAL. Integrated Urgent Care Key Performance Indicators and Quality Standards Page 1 of 20

Barnet Health Overview and Scrutiny Committee 6 October 2016

ALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS

The code: Standards of conduct, performance and ethics for nurses and midwives

The code. Standards of conduct, performance and ethics for nurses and midwives

University College Hospital. The Specialist Centre for Head and Neck Cancer. Information for patients and carers

Chief Officer following agreed delegation from February 2014 Governing Body Date approved: 6 th March 2014

Policy on the Commissioning of NHS Continuing Healthcare for Adults: Assuring Equity, Choice and Value for Money

Commissioning Policy (WM12) Patients Changing Responsible Commissioner. Version 2 February 2012

How to use NICE guidance to commission high-quality services

Strengthening Communities Funding Guidelines

2. Audience The audience for this document is the London NHS Commissioner MCA Steering Board.

Performance and Quality Committee

abcdefghijklmnopqrstu

RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO ACCESS TO MEDICAL TECHNOLOGIES IN WALES

Head of Joint Commissioning committee/individual: Effective from: 6 th February Review date: April 2017

Specialised Services Service Specification: Inherited Bleeding Disorders

Policy Document Control Page

Enhanced service specification. Avoiding unplanned admissions: proactive case finding and patient review for vulnerable people 2016/17

Proposals to implement standards for congenital heart disease services for children and adults in England - Consultation Summary

Wandsworth CCG. Continuing Healthcare Commissioning Policy

NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST. PATIENT ACCESS MANAGEMENT POLICY (Previously known as Waiting List Management Policy) Documentation Control

Are you responding as an individual or on behalf of an organisation?

Appendix 1. Policy on the Dissemination, Implementation and Monitoring of National Clinical Guidance

England. Questions and Answers. Draft Integrated Care Provider (ICP) Contract - consultation package

Decision-Making Business Case

TOPIC 9 - THE SPECIALIST PALLIATIVE CARE TEAM (MDT)

Pilot of the Activity Capture and Attribution Template (ACAT) and ACAT Review service for clinical research grants.

Specialised Services Service Specification: CP57b. Genetic Testing for Inherited Cardiac Conditions

NHS England Complaints Policy

The Pulmonary Hypertension Service Specification (Adult)

Management of surge and escalation in critical care services: standard operating procedure for adult respiratory extra corporeal membrane oxygenation

Implementation Plan for the UK Strategy for Rare Diseases

South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide

Management of surge and escalation in critical care services: standard operating procedure for Adult and Paediatric Burn Care Services in England and

Specialised Services Service Specification. Adult Congenital Heart Disease

ACTION TAKEN UNDER DELEGATED POWERS BY OFFICER 27 th March Contracts Award for Accommodation and Support Services (Lot 1 Support at Home)

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

How NICE clinical guidelines are developed

Physiotherapy outpatient services survey 2012

PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide

The Christie International School of Oncology

Innovating for Improvement

Independent Mental Health Advocacy. Guidance for Commissioners

NHS public health functions agreement Service specification No.2 Neonatal BCG immunisation programme

PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM)

Good Practice in the Transfer of Service User Care & Support between Trusts and Local Authority Areas

Note: This booklet applies to applicants trained outside of the European Economic Area (EEA).

This document is uncontrolled once printed. Please check on the CCG s Intranet site for the most up to date version

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

Section 19 Mental Health Act 1983 Regulations as to the transfer of patients

Policy for Overseas Visitors

Non Attendance (Did Not Attend-DNA ) Policy. Executive Director of Nursing and Chief Operating Officer

Ordinary Residence and Continuity of Care Policy

Policy: L5. Patients Leave Policy (non Broadmoor) Version: L5/01. Date ratified: 8 th August 2012 Title of originator/author:

Implied Consent Model and Permission to View

Sara Barrington Acting Head of CHC

Safeguarding Vulnerable People Annual Report

CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

Supporting information for implementing NMC standards for pre-registration nursing education

Reservation of Powers to the Board & Delegation of Powers

Learning from the Deaths of Patients in our Care Policy

Consultant to Consultant Referral Policy

ASSESSMENT PROCESS FOR NHS CONTINUING HEALTH CARE OPERATIONAL GUIDANCE FOR PRACTITIONERS

NHS National Services Scotland. Equality Impact Assessment Initial Screening Tool

Extended access to general practice. A guide to completing the extended access survey

Patient and Public Voice Assurance Group (PPV AG) for Specialised Commissioning Assurance Report 2017/18

Wig and Hair Replacement Policy

Issue date: October Guide to the multiple technology appraisal process

BOARD PAPER - NHS ENGLAND. Internal Delegation arrangements for Greater Manchester Devolution

NHS Continuing Healthcare Choice Policy Supporting people in Dorset to lead healthier lives

CONSENT TO EXAMINATION OR TREATMENT

Safeguarding Alerts Policy and Procedure

WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0

WOLVERHAMPTON CLINICAL COMMISSIONING GROUP. Corporate Parenting Board. Date of Meeting: 23 rd Feb Agenda item: ( 7 )

16 May Elizabeth James Director of Clinical Commissioning, Barnet CCG

National Cancer Action Team. National Cancer Peer Review Programme EVIDENCE GUIDE FOR: Colorectal MDT. Version 1

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy

LCA Escalation Policy. April 2013

GPs apply for inclusion in the NI PMPL and applications are reviewed against criteria specified in regulation.

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

OFFICIAL. NHS England s National Report to Ministers on the Responsible Officer Regulations and Medical Revalidation, 2016/17

Guidance on Referral Processes between:

Transcription:

Standard Operating Procedure: Process for applying for Proton Beam Therapy and subsequent treatment centre allocation for eligible patients

Document Title: Standard Operating Procedure: Process for applying for Proton Beam Therapy and subsequent treatment centre allocation for eligible patients Version number: 1.0 First published: November 2018 Updated: (only if this is applicable) Prepared by: Iain Mellis, PBT Programme Delivery Lead, NHS England Classification: This information can be made available in alternative formats, such as easy read or large print, and may be available in alternative languages, upon request. Please contact PBT Programme Team on england.pbtpmo@nhs.net. 2

Contents Contents... 3 Standard Operating Procedure statement... 4 Equality and Health Inequalities statement... 4 1 Introduction... 5 2 Background... 5 3 Timescales... 6 4 Application Process... 6 5 Decisions & Treatment Centre Selection... 10 3

Standard Operating Procedure statement This document sets out how the process for applying for Proton Beam Therapy (PBT) and the subsequent treatment centre allocation of eligible patients will operate during the period between October 2018 and March 2021. This version reflects any changes made as a result of stakeholder engagement. Equality and Health Inequalities statement Promoting equality and addressing health inequalities are at the heart of NHS England s values. Throughout the development of the policies and processes cited in this document we have: given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it, and given regard to the need to reduce inequalities between patients in access to, and outcome from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities. 4

1 Introduction 1.1 This document sets out how the process for applying for Proton Beam Therapy (PBT) and the subsequent treatment centre selection of eligible patients will operate during the period between October 2018 and March 2021. 1.2 The intended audience is those responsible for managing the commissioned PBT capacity available to the NHS. It should be read in conjunction with the NHS England commissioning policies relating to the provision of PBT which can be found at: https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b01/ https://www.england.nhs.uk/commissioning/spec-services/highly-specservices/pbt/ 1.3 NHS England is the statutory body responsible for the commissioning of PBT services. The policies that can be found following the above links set out which patients are eligible for PBT and the support that NHS England will provide for patients to access services. 1.4 There is a single process for the operational management of applications for PBT, including the allocation of treatment centre. This process is managed by the National Proton Office. 1.5 It should be noted that the first part of the standard operating procedure applies to all applications for PBT. The second part applies where there is a need to allocate eligible patients (i.e. those whose application has been approved) to an NHS commissioned PBT provider. All patients eligible for PBT through NHS England clinical commissioning policy will be offered treatment at an NHS commissioned provider. 2 Background 2.1 NHS England has been referring patients eligible for PBT overseas for treatment since 2008. The routine commissioned providers of this service are University of Florida Health Proton Institute, Jacksonville, USA and Westdeutsches Protonentherapiezentrum (WPE) Essen, Germany. Both centres have been through a full NHS England procurement or quality assurance process and both are fully compliant with the NHS England Service Specification for overseas PBT providers which can be found at:https://www.england.nhs.uk/publication/servicespecifications-proton-beam-therapy-service-adults-and-children/ 2.2 On occasion, some adult patients may be treated at the Paul Scherrer Institut, Villigen, Switzerland. This will particularly be for those patients unable to travel to the United States for either clinical or other personal issues such as visa restrictions 5

2.3 In Autumn 2018, the first of two NHS PBT centres will open at The Christie Hospital NHS Foundation Trust in Manchester. The second NHS PBT centre will open in Summer 2020 at University College London Hospitals NHS Foundation Trust. 2.4 The NHS PBT centres will go through a period of clinical and capacity ramp-up during which time the clinical indications and number of patients able to be treated within these centres will increase to a point at which it will no longer be necessary to refer any NHS patients overseas for treatment. It is anticipated this will be by March 2021. 2.5 It is anticipated that once both NHS PBT centres are at full capacity, the majority of referrals will be geographically based, i.e. referrals from the north of England, including from Scotland, Northern Ireland and north Wales will be to The Christie and those from the south of England to UCLH. 2.6 Until the NHS PBT service has sufficient capacity to treat all NHS patients, the default referral route will be to established routine commissioned providers overseas. 2.7 NHS England will only fund referrals made to PBT centres commissioned by NHS England. 3 Timescales 3.1 The standard period for providing a substantive response to an application for PBT (i.e. a decision on the patient s eligibility and allocated treatment centre) is a maximum of 10 working days from the date of receipt of a fully completed application to the date the applying clinician is informed of the outcome. Urgent cases will be considered and responded to within 2 working days. 4 Application Process 4.1 All applications for PBT must be made using the web-based Proton Referral Portal. All applying clinicians must be registered to access this portal. Details of how to register can also be found following this link https://protons.protontherapyreferrals.nhs.uk 4.2 Referrals can only be made by a Consultant Clinical Oncologist from an NHS specialised cancer centre following discussion at the relevant MDT meeting. Applications cannot be accepted from GPs, patients or their non-clinical representatives. This is because: it is unlikely they would be in possession of the technical clinical detail including imaging that is necessary for consideration of the application 6

the process is designed to enable an NHS clinician to apply for commissioning approval to support the referral for NHS treatment to the appropriate NHS England commissioned provider. 4.3 It is important that any social or logistical problems that might impact on patient care, safeguarding or ability of the patient or family to manage travel or treatment abroad are fully explored and must be contained within the referral. 4.4 Consent for treatment(s) or any associated clinical trials will be undertaken at the treatment centre, once the treating clinician has met and assessed the patient. However, patients will be informed of the need to transfer detailed information about their case, including test results and scans through the NHS Referral Portal in order to be assessed for funding and approval. If approved, it will be necessary to transfer information from the referring centre to the treatment centre, which may be abroad. Written consent for follow up data to be used for the purposes of clinical audit, service evaluation and improvement and health care research will also be taken by the referring clinical team. Follow-up data will be held at the treating centre. Anonymised data may be shared for the purposes outlined. 4.5 The Referral Portal is designed to ensure applications contain all necessary information for a decision to be made and applications cannot be submitted without all mandatory fields completed. 4.6 Imaging must be sent through Image Exchange Portal (IEP) from the referring hospital. 4.7 Complete PBT applications will then be circulated via the portal to one of the PBT National Clinical Panels, virtual panels made up of leading oncologists and specialist surgeons from across the UK. Panels are currently in place for: Paediatric and Teenage & Young Adult (TYA) Cancers Adult Skull base and Central Nervous System (CNS) Spinal and Sacral Tumours (Adult and TYA) Head and Neck Tumours (Adult and TYA) 4.8 The panel will individually review the application and supporting documentation. Panel members can see imaging through a secure PBT version of IEP (which is also used for transferring images abroad as this complies with international governance). 4.9 Panel members send replies back via the portal on recommendation about approval and clinical management, including whether the case meets clinical criteria. They will also provide comments about the case and especially on safety of treatment overseas or timing of treatment. If there is a NO response, further detail on the reasons why is included. 7

4.10 The PBT National Clinical Panel Chair will review the responses from the panel and make a recommendation/decision as to whether or not the patient meets the NHS England commissioning criteria. A minimum of three consistent replies are needed before making a decision for paediatric and TYA and Skull Base patients, and two consistent replies for Head and Neck and Spinal patients. In the event of a lack of consensus the Chair will facilitate further discussion via email to reach a consensus view. This may include clarifying any misunderstanding on clinical criteria or poor application details. In particularly difficult cases the Chair may wait for or seek more replies before a final decision is made. On occasion, further advice may be sought from proton clinical experts at one or more of NHS England s commissioned providers prior to a final decision being made. 4.11 The Chair will send a formal reply to referring clinicians including feedback from panel members especially in the event of a NO decision. 4.12 For applications that meet the NHS England commissioning criteria, the PBT National Clinical Panel chair through delegated authority from NHS England, confirms in writing to the clinician making the application that a referral can be made to one of the PBT providers commissioned by NHS England. This may include feedback from panel members. The National Proton Office sends a copy of travel and accommodation policy plus the PBT centre referral checklist if appropriate, with a YES decision. 4.13 For applications that do not meet the NHS England commissioning criteria, the PBT National Clinical Panel Chair through delegated authority from NHS England confirms in writing to the clinician making the application that the patient does not meet the eligibility criteria and that a referral for PBT may not be made. This will include relevant feedback from panel members. 4.14 It is the responsibility of the referring clinical team to communicate the commissioning decision and rationale to the patient and family. 4.15 All panel and commissioning replies are kept on file within the portal. 8

4.16 PBT Referral Pathway Site specific referral centre MDT Decision to refer patient for PBT PBT Referral Portal Submission of patient referral information including imaging National PBT Clinical Panel Virtual panel assess application for PBT against NHS clinical commissioning policy Patient not eligible for PBT Patient eligible for PBT PBT Centre does not confirm acceptance on clinical or technical grounds Referring clinician and PBT Admin notified Patient referred to NHS Provider Refer to National PBT programme provider Discussed at NHS commissioned PBT Centre site specific MDT Review referral See below Key Discussion Patient Pathway Confirmed Decision to accept referral and invite patient for assessment 9

5 Decisions & Treatment Centre Selection 5.1 In confirming that an application has been successful and that a patient is eligible for PBT, the PBT National Clinical Panel chair will make a recommendation as to which NHS England commissioned PBT centre the patient should be referred. 5.2 The National Proton Office will have the following options available to them: Referral to an overseas provider: WPE, Essen, Germany (paediatric only) UFHPTI, Jacksonville, USA (all ages) PSI, Villigen, Switzerland (adults only) Referral to an NHS PBT Centre The Christie, Manchester (from 2018) (paediatric and TYA from 2018, all ages from 2019) UCLH (from 2020) (all ages) 5.3 The National Proton Office will allocate patients to a treatment centre following the framework below which has been designed following public engagement and consultation. The patient s clinical circumstances will always take priority. Other factors may be taken into consideration after it is confirmed that the patient s clinical circumstances are not the primary factor. It is essential that the capacity and operational resilience of the PBT treatment centres (especially those in the early stages of development) is maintained to ensure provision of high quality and robust services to all NHS patients. 5.4 In order to appropriately allocate a patient to a treatment centre, it is essential that applications are fully completed and include information on any personal and/or family circumstances that may be taken into account by the National Proton Office when making a decision. These include (but not limited to): Tier 1 (absolute) Non-clinical restrictions on travel for either patient or carer (e.g. visa restrictions) Pregnancy (2/3 rd Trimester - patient or carer) Safeguarding concerns, including parental access issues Ongoing court and/or legal proceedings preventing travel overseas Physical or mental ill health impacting on carer s ability to travel overseas Tier 2 (additional information that may be taken into account) Other dependants (e.g. siblings or elderly relatives) Single parents Education (especially TYA patients) Relative living close to a PBT centre Work restrictions (e.g. selfemployed, ability to take time off work) 10

5.5 PBT Treatment Centre Allocation Pathway Can the NHS PBT Provider clinically treat the patient? Yes No Does the patient have clinical conditions precluding referral overseas? Does the NHS PBT Provider have the capacity to treat the patient? No Yes Refer to NHS PBT Provider Yes Limited No Refer to National PBT Programme provider Has the patient/family indicated they are willing & to travel overseas? Return to referrer for further discussion No Yes Refer to National PBT Programme provider Does the patient have any personal and/or family circumstances that will impact on referral overseas?* * See Paragraph 5.4 Refer to NHS PBT Provider Yes No Does the patient live within the catchment area* of the NHS PBT centre * See Paragraph 2.4 Refer to NHS PBT Provider Yes No Refer to National PBT Programme provider 11

5.6 If the patient is approved for treatment and recommended to an NHS PBT centre, the patient will be referred directly onto the centre with clinical information transferred via the referral portal. 5.7 If the patient is approved for treatment and recommended to an NHS England commissioned overseas provider, then the referring clinician will need to download the application from the portal and send this as the referral directly to the recommended overseas provider, along with any updated or additional material requested by them. 12